

# Analysis of an Anti-GnRH Chimeric Antibody Purified from Tobacco Leaves

Richa Nath\*, Markus Sack\*, Ricarda Finnern§, G. P. Talwar+ and Rainer Fischer\*,§

\*Institute for Molecular Biotechnology, RWTH Aachen, Germany, §Fraunhofer-IME, Aachen, Germany,


+Talwar Research Foundation, New Delhi, India

## Introduction


Gonadotropin releasing hormone (GnRH), a decapeptide neurohormone, is the key regulator of the reproductive hormone cascade. The effect of immunoneutralisation of GnRH is equivalent to the GnRH antagonists that are widely used for various clinical conditions, like:-

- Prostate cancer
- Breast cancer
- Endometriosis
- Precocious puberty
- ART (artificial reproductive technology)

Presented here is the characterisation of a mouse-human **chimeric antibody (chiP<sub>7278</sub>)** recognizing GnRH, transiently expressed in tobacco leaves by vacuum assisted agroinfiltration. The variable domains of the chiP<sub>7278</sub> were cloned from a well characterized **monoclonal antibody (mAbP<sub>7278</sub>)** having high affinity for GnRH.




## Stability of mAbP<sub>7278</sub> and chiP<sub>7278</sub> in human serum at 37°C in vitro



Antibody activity after 32 days at 37°C in human serum  
chiP<sub>7278</sub> – 70%  
mAbP<sub>7278</sub> – 60%

Determination of active antibody concentration (at each time point) by BIAcore


## Transient expression and purification of chiP<sub>7278</sub>



Affinity purification of chiP<sub>7278</sub> from tobacco leaves infiltrated with a mixture of two independent agrobacterium populations containing the chimeric heavy and light chain genes cloned in plant expression vector, pSSH<sup>H1</sup>


**Yield:**  
8mg of antibody per kg of tobacco leaf material

## ChiP<sub>7278</sub> recognises GnRH II and GnRH III, the two recently discovered isoforms in humans



Incubation of ChiP<sub>7278</sub> with a 1000 fold excess of the peptides completely inhibits the antibody from binding to the D-Lys(6)-GnRH coated chip on the BIAcore.


## Bionutralisation of LHRH causes estrus suppression in rodents



E – estrus D – diestrus ↑ - day of injection  
Estrus cycle monitored by vaginal cytology study

Intra-peritoneal injection of GnRH specific antibodies given to regularly cycling rodents causes a dose dependent suppression of the estrus cycle, a consequence of the disruption of hypothalamic-pituitary-gonadal axis.

## Indistinguishable affinities of chiP<sub>7278</sub> (3.4x10<sup>-10</sup> M<sup>-1</sup>) and mAbP<sub>7278</sub> (3.5x10<sup>-10</sup> M<sup>-1</sup>)



The molecular interaction between GnRH and the antibodies was analysed using the BIAcore system using a homogenous phase assay. Experiments were carried out under mass transport limitation (MTL = 0.86) measuring concentrations of antibodies having one or both binding sites free. The inhibitory constant  $K_i$  and the concentration of the antibody were determined by non-linear least square fit using the given equation:

$$m = m^0 \cdot \left( 1 - \frac{1}{16 \cdot C_{total}^2} \cdot \left\{ \left[ K_i + 2 \cdot C_{total} + L_{total} \right] - \sqrt{\left( K_i + 2 \cdot C_{total} + L_{total} \right)^2 - 8 \cdot L_{total} \cdot C_{total}} \right\}^2 \right)$$

$K_i$  = Inhibitory constant;  $C_{total}$  = total antibody concentration;  $L_{total}$  = total GnRH concentration;  $m$  = observed binding rate;  $m^0$  = observed binding rate without peptide

## Conclusion and future perspectives

The plant expressed chiP<sub>7278</sub> was shown to have indistinguishable affinities from the parental antibody, highly stable and capable of neutralizing GnRH in vivo to cause a bio-effect, demonstrating its ability to disrupt the hypothalamo-pituitary-gonadal axis. The anti-GnRH antibodies have the potential for use as a natural, convenient and non-surgical mode of therapy for many clinical conditions that will benefit from the down regulation of the reproductive hormones. Molecular farming of the recombinant antibody will enable production of large amounts of the antibody, a prerequisite for the development of any drug. The ability of the antibody to bind to the GnRH isoforms presents exciting possibilities. The antibody can be used to study the role and localisation of the peptide variants. Protein engineering might be used to evolve derivatives of P<sub>7278</sub> that can discriminate between the different isoforms facilitating the research.